Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of RC108 injection in c-Met-positive advanced gastrointestinal malignancies
CTR20222205Phase 2Completed
- Sponsor
- RemeGen
- Start
- Dec 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RC108 in gastrointestinal cancer, sponsored by RemeGen. Started Dec 2022; status: completed.
02
Drugs
RC108
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on CTR20222205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222205.